Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2006 1
2007 1
2008 3
2009 1
2010 5
2011 4
2012 8
2013 6
2014 8
2015 8
2016 7
2017 19
2018 24
2019 15
2020 18
2021 16
2022 17
2023 24
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

175 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for yan xin tu
Search for Yanxin Tu instead (2 results)
A Randomized, Placebo-Controlled Study of Methotrexate to Increase Response Rates in Patients with Uncontrolled Gout Receiving Pegloticase: Primary Efficacy and Safety Findings.
Botson JK, Saag K, Peterson J, Parikh N, Ong S, La D, LoCicero K, Obermeyer K, Xin Y, Chamberlain J, LaMoreaux B, Verma S, Sainati S, Grewal S, Majjhoo A, Tesser JRP, Weinblatt ME. Botson JK, et al. Among authors: xin y. Arthritis Rheumatol. 2023 Feb;75(2):293-304. doi: 10.1002/art.42335. Epub 2022 Dec 16. Arthritis Rheumatol. 2023. PMID: 36099211 Free PMC article. Clinical Trial.
Cancer Stem Cell for Tumor Therapy.
Huang B, Yan X, Li Y. Huang B, et al. Among authors: yan x. Cancers (Basel). 2021 Sep 26;13(19):4814. doi: 10.3390/cancers13194814. Cancers (Basel). 2021. PMID: 34638298 Free PMC article. Review.
In this review, we provide a comprehensive understanding of the biological characteristics of CSCs, including mitotic pattern, metabolic phenotype, therapeutic resistance and related mechanisms. Finally, we summarize CSCs targeted strategies, including targeting CSCs surfa …
In this review, we provide a comprehensive understanding of the biological characteristics of CSCs, including mitotic pattern, metabolic phe …
CD58 loss in tumor cells confers functional impairment of CAR T cells.
Yan X, Chen D, Ma X, Wang Y, Guo Y, Wei J, Tong C, Zhu Q, Lu Y, Yu Y, Wu Z, Han W. Yan X, et al. Blood Adv. 2022 Nov 22;6(22):5844-5856. doi: 10.1182/bloodadvances.2022007891. Blood Adv. 2022. PMID: 35728062 Free PMC article.
In summary, we describe a potential mechanism of tumor-intrinsic resistance to CAR T-cell therapy and suggest that this mechanism may be leveraged for developing therapeutic strategies to overcome resistance to CAR T-cell therapy in B-cell malignancies....
In summary, we describe a potential mechanism of tumor-intrinsic resistance to CAR T-cell therapy and suggest that this mechanism may be lev …
Identification of NOXA as a pivotal regulator of resistance to CAR T-cell therapy in B-cell malignancies.
Yan X, Chen D, Wang Y, Guo Y, Tong C, Wei J, Zhang Y, Wu Z, Han W. Yan X, et al. Signal Transduct Target Ther. 2022 Apr 4;7(1):98. doi: 10.1038/s41392-022-00915-1. Signal Transduct Target Ther. 2022. PMID: 35370290 Free PMC article.
Pharmacological targeting of NOXA might provide an innovative therapeutic strategy to enhance CAR T-cell therapy....
Pharmacological targeting of NOXA might provide an innovative therapeutic strategy to enhance CAR T-cell therapy....
Bioinformatics-integrated screening of systemic sclerosis-specific expressed markers to identify therapeutic targets.
Jin J, Liu Y, Tang Q, Yan X, Jiang M, Zhao X, Chen J, Jin C, Ou Q, Zhao J. Jin J, et al. Among authors: yan x. Front Immunol. 2023 Mar 30;14:1125183. doi: 10.3389/fimmu.2023.1125183. eCollection 2023. Front Immunol. 2023. PMID: 37063926 Free PMC article.
Eventually, we found that MALAT1-miR-206-CCL2, let-7a-5p-IL6, and miR-196a-5p-SERPINE1 may be promising RNA regulatory pathways in SSc. Besides, ten potential therapeutic drugs associated with the hub gene were identified. CONCLUSIONS: This study revealed tissue-specific e …
Eventually, we found that MALAT1-miR-206-CCL2, let-7a-5p-IL6, and miR-196a-5p-SERPINE1 may be promising RNA regulatory pathways in SSc. Besi …
Circular RNAs: a new frontier for cancer diagnosis and therapy.
Zhang M, Xin Y. Zhang M, et al. Among authors: xin y. J Hematol Oncol. 2018 Feb 13;11(1):21. doi: 10.1186/s13045-018-0569-5. J Hematol Oncol. 2018. PMID: 29433541 Free PMC article. Review.
This brief review introduces circRNAs by describing their potential as a biomarker and therapeutic target and discussing the possible strategies to target them. ...
This brief review introduces circRNAs by describing their potential as a biomarker and therapeutic target and discussing the possible …
Functional Selection of Tau Oligomerization-Inhibiting Aptamers.
Wang B, Pan X, Teng IT, Li X, Kobeissy F, Wu ZY, Zhu J, Cai G, Yan H, Yan X, Liang M, Yu F, Lu J, Yang Z, Biondi E, Haskins W, Cao YC, Benner SA, Tan W, Wang KK. Wang B, et al. Among authors: yan x. Angew Chem Int Ed Engl. 2024 Apr 24;63(18):e202402007. doi: 10.1002/anie.202402007. Epub 2024 Mar 14. Angew Chem Int Ed Engl. 2024. PMID: 38407551
Targeting MYH9 represses USP14-mediated NAP1L1 deubiquitination and cell proliferation in glioma.
Chen Z, Yan X, Miao C, Liu L, Liu S, Xia Y, Fang W, Zheng D, Luo Q. Chen Z, et al. Among authors: yan x. Cancer Cell Int. 2023 Sep 28;23(1):220. doi: 10.1186/s12935-023-03050-1. Cancer Cell Int. 2023. PMID: 37770914 Free PMC article.
Altogether, our results show that MYH9 plays a role in glioma progression by regulating NAP1L1 deubiquitination. Thus, targeting MYH9 is a potential therapeutic strategy for the clinical treatment of glioma in the future....
Altogether, our results show that MYH9 plays a role in glioma progression by regulating NAP1L1 deubiquitination. Thus, targeting MYH9 is a p …
175 results